56 related articles for article (PubMed ID: 38591867)
21. Dabrafenib and Trametinib in Patients With Tumors With
Salama AKS; Li S; Macrae ER; Park JI; Mitchell EP; Zwiebel JA; Chen HX; Gray RJ; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Armstrong DK; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
J Clin Oncol; 2020 Nov; 38(33):3895-3904. PubMed ID: 32758030
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of osimertinib against EGFRvIII+ glioblastoma.
Chagoya G; Kwatra SG; Nanni CW; Roberts CM; Phillips SM; Nullmeyergh S; Gilmore SP; Spasojevic I; Corcoran DL; Young CC; Ballman KV; Ramakrishna R; Cross DA; Markert JM; Lim M; Gilbert MR; Lesser GJ; Kwatra MM
Oncotarget; 2020 Jun; 11(22):2074-2082. PubMed ID: 32547705
[TBL] [Abstract][Full Text] [Related]
23. A Rare EGFR-SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib.
Li Y; Zhang HB; Chen X; Yang X; Ye Y; Bekaii-Saab T; Zheng Y; Zhang Y
Oncologist; 2020 Mar; 25(3):203-207. PubMed ID: 32162810
[TBL] [Abstract][Full Text] [Related]
24. Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis.
Liu H; Zhang B; Sun Z
Cancer Commun (Lond); 2020 Jan; 40(1):43-59. PubMed ID: 32067422
[TBL] [Abstract][Full Text] [Related]
25. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design.
Flaherty KT; Gray R; Chen A; Li S; Patton D; Hamilton SR; Williams PM; Mitchell EP; Iafrate AJ; Sklar J; Harris LN; McShane LM; Rubinstein LV; Sims DJ; Routbort M; Coffey B; Fu T; Zwiebel JA; Little RF; Marinucci D; Catalano R; Magnan R; Kibbe W; Weil C; Tricoli JV; Alexander B; Kumar S; Schwartz GK; Meric-Bernstam F; Lih CJ; McCaskill-Stevens W; Caimi P; Takebe N; Datta V; Arteaga CL; Abrams JS; Comis R; O'Dwyer PJ; Conley BA;
J Natl Cancer Inst; 2020 Oct; 112(10):1021-1029. PubMed ID: 31922567
[TBL] [Abstract][Full Text] [Related]
26. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC;
Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
[TBL] [Abstract][Full Text] [Related]
27. Clinical activity of the
Makhlin I; Salinas RD; Zhang D; Jacob F; Ming GL; Song H; Saxena D; Dorsey JF; Nasrallah MP; Morrissette JJ; Binder ZA; O'Rourke DM; Desai AS; Brem S; Bagley SJ
CNS Oncol; 2019 Nov; 8(3):CNS43. PubMed ID: 31769726
[TBL] [Abstract][Full Text] [Related]
28. Overall Survival with Osimertinib in Untreated,
Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Marabelle A; Le DT; Ascierto PA; Di Giacomo AM; De Jesus-Acosta A; Delord JP; Geva R; Gottfried M; Penel N; Hansen AR; Piha-Paul SA; Doi T; Gao B; Chung HC; Lopez-Martin J; Bang YJ; Frommer RS; Shah M; Ghori R; Joe AK; Pruitt SK; Diaz LA
J Clin Oncol; 2020 Jan; 38(1):1-10. PubMed ID: 31682550
[TBL] [Abstract][Full Text] [Related]
30. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.
Harrison PT; Vyse S; Huang PH
Semin Cancer Biol; 2020 Apr; 61():167-179. PubMed ID: 31562956
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Drilon A; Laetsch TW; Kummar S; DuBois SG; Lassen UN; Demetri GD; Nathenson M; Doebele RC; Farago AF; Pappo AS; Turpin B; Dowlati A; Brose MS; Mascarenhas L; Federman N; Berlin J; El-Deiry WS; Baik C; Deeken J; Boni V; Nagasubramanian R; Taylor M; Rudzinski ER; Meric-Bernstam F; Sohal DPS; Ma PC; Raez LE; Hechtman JF; Benayed R; Ladanyi M; Tuch BB; Ebata K; Cruickshank S; Ku NC; Cox MC; Hawkins DS; Hong DS; Hyman DM
N Engl J Med; 2018 Feb; 378(8):731-739. PubMed ID: 29466156
[TBL] [Abstract][Full Text] [Related]
32. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
33. Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial.
Khoury JD; Wang WL; Prieto VG; Medeiros LJ; Kalhor N; Hameed M; Broaddus R; Hamilton SR
Clin Cancer Res; 2018 Feb; 24(3):521-531. PubMed ID: 28839110
[TBL] [Abstract][Full Text] [Related]
34. Response Assessment in Neuro-Oncology Clinical Trials.
Wen PY; Chang SM; Van den Bent MJ; Vogelbaum MA; Macdonald DR; Lee EQ
J Clin Oncol; 2017 Jul; 35(21):2439-2449. PubMed ID: 28640707
[TBL] [Abstract][Full Text] [Related]
35. Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial.
Lih CJ; Harrington RD; Sims DJ; Harper KN; Bouk CH; Datta V; Yau J; Singh RR; Routbort MJ; Luthra R; Patel KP; Mantha GS; Krishnamurthy S; Ronski K; Walther Z; Finberg KE; Canosa S; Robinson H; Raymond A; Le LP; McShane LM; Polley EC; Conley BA; Doroshow JH; Iafrate AJ; Sklar JL; Hamilton SR; Williams PM
J Mol Diagn; 2017 Mar; 19(2):313-327. PubMed ID: 28188106
[TBL] [Abstract][Full Text] [Related]
36. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis.
Zhang YL; Yuan JQ; Wang KF; Fu XH; Han XR; Threapleton D; Yang ZY; Mao C; Tang JL
Oncotarget; 2016 Nov; 7(48):78985-78993. PubMed ID: 27738317
[TBL] [Abstract][Full Text] [Related]
37. RECIST 1.1-Update and clarification: From the RECIST committee.
Schwartz LH; Litière S; de Vries E; Ford R; Gwyther S; Mandrekar S; Shankar L; Bogaerts J; Chen A; Dancey J; Hayes W; Hodi FS; Hoekstra OS; Huang EP; Lin N; Liu Y; Therasse P; Wolchok JD; Seymour L
Eur J Cancer; 2016 Jul; 62():132-7. PubMed ID: 27189322
[TBL] [Abstract][Full Text] [Related]
38. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
Yang JC; Sequist LV; Geater SL; Tsai CM; Mok TS; Schuler M; Yamamoto N; Yu CJ; Ou SH; Zhou C; Massey D; Zazulina V; Wu YL
Lancet Oncol; 2015 Jul; 16(7):830-8. PubMed ID: 26051236
[TBL] [Abstract][Full Text] [Related]
39. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
Chiu CH; Yang CT; Shih JY; Huang MS; Su WC; Lai RS; Wang CC; Hsiao SH; Lin YC; Ho CL; Hsia TC; Wu MF; Lai CL; Lee KY; Lin CB; Yu-Wung Yeh D; Chuang CY; Chang FK; Tsai CM; Perng RP; Chih-Hsin Yang J
J Thorac Oncol; 2015 May; 10(5):793-799. PubMed ID: 25668120
[TBL] [Abstract][Full Text] [Related]
40. The integrated landscape of driver genomic alterations in glioblastoma.
Frattini V; Trifonov V; Chan JM; Castano A; Lia M; Abate F; Keir ST; Ji AX; Zoppoli P; Niola F; Danussi C; Dolgalev I; Porrati P; Pellegatta S; Heguy A; Gupta G; Pisapia DJ; Canoll P; Bruce JN; McLendon RE; Yan H; Aldape K; Finocchiaro G; Mikkelsen T; Privé GG; Bigner DD; Lasorella A; Rabadan R; Iavarone A
Nat Genet; 2013 Oct; 45(10):1141-9. PubMed ID: 23917401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
